Working… Menu

Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04874831
Recruitment Status : Not yet recruiting
First Posted : May 6, 2021
Last Update Posted : July 6, 2021
Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):

Tracking Information
First Submitted Date  ICMJE April 15, 2021
First Posted Date  ICMJE May 6, 2021
Last Update Posted Date July 6, 2021
Estimated Study Start Date  ICMJE July 2021
Estimated Primary Completion Date September 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 30, 2021)
Confirmed Objective Response (OR) [ Time Frame: up to 1 year ]
Confirmed Objective Response (OR) according to RECIST vl.l, determined by independent review. Both Complete Response and Partial Response must be confirmed by a second tumor assessment preferably at the regularly scheduled 6-weeks assessment interval, but no sooner than 4 weeks after the initial diagnosis of CR or PR.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 30, 2021)
  • Duration of Response (DOR) [ Time Frame: up to 1 year ]
    Duration of Response (DOR) according to RECIST vl.l as determined by independent review.
  • Durable Response (DR) [ Time Frame: up to 1 year ]
    Durable Response (DR) according to RECIST vl.l, defined as objective response (CR or PR) determined by independent review with duration of at least 6 months.
  • Overall Survival (OS) [ Time Frame: approx 3.5 years ]
    Overall Survival (OS) time, defined as the time from the first administration of study treatment until death due to any cause determined by the Investigator.
  • Progression Free Survival (PFS) [ Time Frame: approx. 3 years ]
    Progression Free Survival (PFS) according to RECIST vl.l, defined as the time from first dosing (Day 1) to the date of PD or death from any cause (whichever comes first) as determined by independent review.
  • Disease Control (DC) [ Time Frame: up to 1 year ]
    Disease Control (DC) according to RECIST vl.l, defined as the proportion of patients with either an objective response (CR, PR) or stable disease (SD), as determined by independent review.
  • RECIST vl.l response [ Time Frame: up to 1 year ]
    RECIST vl.l responses at 6 and 12 months after start of study treatment as determined by independent review.
  • Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0 [ Time Frame: approx. 3 years ]
    number, frequency, duration and severity of AEs
  • Correlation of biomarker expression to efficacy [ Time Frame: up to 1 year ]
    Correlation of ORR, DOR, DR, DC and PFS to biomarker expression determined by immunohistochemistry.
  • Anti-drug-antibodies (ADAs) [ Time Frame: up to 1 year ]
    Anti-drug-antibodies (ADAs) treatments.
  • Health related Quality of Life determined by the questionnaire FACT-M [ Time Frame: up to 1 year ]
    The impact of treatment on the patient's QoLwill be assessed with the questionnaire "Functional Assessment of Cancer Therapy - Melanoma (FACT-M)" where QoL is assessed on a scale 0-240 (higher score means better status of health)
  • Plasma concentration of domatinostat and avelumab [ Time Frame: up to 1 year ]
    Single trough values of domatinostat and avelumab at pre-defined time points
  • Health related Quality of Life determined by the questionnaire EQ-5D-5L [ Time Frame: up to 1 year ]
    The impact of treatment on the patient's QoLwill be assessed with the questionnaire "EQ-5D-5L" which is a multi attribute utility instrument for measuring health-related QoL as EQ5D index with a score 0-1 (higher score means better status of health)
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
Official Title  ICMJE A Phase II, Open Label, Multicenter Study to Investigate the Efficacy and Safety of Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma - the MERKLIN 1 Study
Brief Summary This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with treatment-naïve metastatic Merkel Cell Carcinoma
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Merkel Cell Carcinoma
Intervention  ICMJE Drug: domatinostat in combination with avelumab
domatinostat tablets and avelumab infusion
Study Arms  ICMJE Experimental: domatinostat and avelumab
Single arm study of Domatinostat tablets in combination with avelumab infusion
Intervention: Drug: domatinostat in combination with avelumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: April 30, 2021)
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 2026
Estimated Primary Completion Date September 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Signed written informed consent.
  2. Age 18 years at signature of Informed Consent Form (ICF).
  3. Histologically proven MCC.

    • Confirmation of the diagnosis by immune-histochemistry as per standard at the institution, including (but not limited to) CK20 and TTF-1.
    • Patients must have metastatic or distally recurrent disease; Ml status must be confirmed at entry.
    • Patients must not have received any prior systemic treatment for metastatic MCC. Prior treatment in the adjuvant setting (no clinically detectable disease; no metastatic disease) will be allowed, if the end of the treatment occurred at least 6 months prior to study entry, i.e. signing ICF.
  4. Fresh biopsy or archival tumor tissue (not older than 3 months) from an unirradiated lesion.
  5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at study entry.
  6. Estimated life expectancy of more than 12 weeks.
  7. Disease must be measurable with at least one unidimensional measurable lesion by RECIST vl.l (including skin lesions).
  8. Adequate hematological and organ function defined by the following parameters:

    Adequate hematological function defined by

    • White blood cell count (WBC) > 3000/pl
    • Absolute Neutrophil Count (ANC) > 1500/pl
    • Lymphocyte count > 500/pl
    • Hemoglobin (Hb) > 9 g/dl (or > 5.6 mmol/L), may have been transfused
    • Platelet count > 100.000/pl

    Adequate hepatic function defined by

    • Serum total bilirubin < 1.5 x ULN
    • ALT and/or AST < 1.5 x ULN

    Adequate renal function defined by

    • eGFR > 60 ml/ min (as per Cockcroft-Gault formula)

  9. Highly effective contraception for both male and female subjects if the risk of conception exists. Female patients of childbearing potential must have a negative urine or serum pregnancy test before receiving the first dose of study medication and must comply with contraception methods as requested by the study protocol.

Exclusion Criteria:

  1. Participation in another interventional clinical study within the past 30 days (participation in observational studies is permitted)
  2. Concurrent treatment with a non-permitted drug.
  3. Prior therapy with any histone deacetylase (HDAC) inhibitor or antibody/drug targeting T cell coregulatory proteins (immune checkpoints) such as anti-programmed death 1 (PD-1), antiprogrammed death-ligand 1 (PD-L1) or anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody.
  4. Concurrent anti-cancer treatment (for example, cytoreductive therapy, radiotherapy, immune therapy, or cytokine therapy except for erythropoietin). Radiotherapy administered to superficial lesions is not allowed if such lesions are considered target lesions in the efficacy evaluation or may influence the efficacy evaluation of the study treatment.
  5. Major surgery for any reason, except diagnostic biopsy, within 4 weeks and/or if the subject has not fully recovered from surgery.
  6. Concurrent systemic therapy with steroids or other immunosuppressive agents (e.g. methotrexate, azathioprine, interferons, mycophenolate, anti-TNF agents and other), or the use of any investigational drug within 28 days before the start of study treatment. Short-term administration of systemic steroids e.g. for allergic reactions or the management of immune-related adverse events [irAE] while on study is allowed. Also, patients requiring hormone replacement with corticosteroids for adrenal insufficiency are eligible if the steroids are administered only for purpose of hormonal replacement and at doses < 10 mg or equivalent prednisone per day.
  7. Conditions requiring systemic anti-arrhythmic therapy known to prolong QT/QTc interval, patients with QTcF interval >480 msec on at least 2 separate and consecutive ECGs at screening or a medical history of long-QT-Syndrome.
  8. Patients with active central nervous system (CNS) metastases are excluded and a brain CT/MRI will be required during screening if not performed within 6 weeks prior to the planned start of the study treatment. Subjects with a history of treated CNS metastases (by surgery or radiation therapy) are not eligible unless they have fully recovered from treatment, demonstrated no progression for at least 2 months, and do not require continued steroid therapy.
  9. History of or concurrent malignancies, except the malignancy is clinically insignificant, no systemic treatment is or has been required for the last 6 months, and the patient is clinically stable
  10. Prior organ transplantation (including allogeneic stem-cell transplantation).
  11. Any active gastrointestinal disorder that could interfere with the absorption of domatinostat characterized by malabsorption or inability to swallow tablets as per judgment of the Investigator.
  12. Positive testing for HIV or known AIDS or HBV or HCV infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening is positive).
  13. Active or history of any autoimmune disease (except for patients with vitiligo) or immune-diseases that required treatment with systemic immune modulating drugs.
  14. History or current evidence of clinically relevant allergies or hypersensitivity, which includes known or suspected intolerabilities attributed to domatinostat or avelumab or to constituents of the domatinostat tablets or avelumab infusion and known severe hypersensitivity reactions (Grade 3) to monoclonal antibodies.
  15. Persisting toxicity related to prior therapy Grade > 1 National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0; however, sensory neuropathy Grade < 2 will be acceptable.
  16. Pregnancy or lactation period.
  17. Known or suspected alcohol or drug abuse.
  18. Clinically significant (i.e. active) cardiovascular and/or thromboembolic diseases:

    • Cerebral vascular accident or stroke < 6 months prior to enrollment.
    • Uncontrolled hypertension
    • Congestive heart failure (New York Heart Association (NYHA) ClassIII or IV)
    • Serious cardiac arrhythmia requiring medication (patients with status post pacemaker and/or defibrillator implantation can be included)
    • Symptomatic ischemic or severe valvular heart disease
    • Unstable angina pectoris or a myocardial infarction within 6 months prior to screening, i.e. signing ICF
  19. All other significant diseases (for example, inflammatory bowel disease), which, in the opinion of the Investigator, might impair the patient s tolerance to the study treatment.
  20. Any psychiatric condition that would prohibit the understanding or rendering of informed consent.
  21. Legal incapacity or limited legal capacity.
  22. Administration of a live vaccine within 28 days prior to study drug administration. Live vaccines are also prohibited during study treatment.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Chief Medical Officer +49 (0)89 700 7630
Listed Location Countries  ICMJE France,   Germany,   Italy,   Netherlands,   Poland,   Spain,   Switzerland
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT04874831
Other Study ID Numbers  ICMJE 4SC-202-4-2019
2019-003575-19 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party 4SC AG
Study Sponsor  ICMJE 4SC AG
Collaborators  ICMJE Merck KGaA, Darmstadt, Germany
Investigators  ICMJE Not Provided
PRS Account 4SC AG
Verification Date April 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP